Beam Therapeutics Files 8-K
Ticker: BEAM · Form: 8-K · Filed: Dec 9, 2024 · CIK: 1745999
| Field | Detail |
|---|---|
| Company | Beam Therapeutics Inc. (BEAM) |
| Form Type | 8-K |
| Filed Date | Dec 9, 2024 |
| Risk Level | low |
| Pages | 6 |
| Reading Time | 7 min |
| Key Dollar Amounts | $0.01 |
| Sentiment | neutral |
Sentiment: neutral
Topics: 8-K, disclosure, regulatory
TL;DR
Beam Therapeutics filed an 8-K on Dec 7, 2024, covering Reg FD, other events, and financials.
AI Summary
Beam Therapeutics Inc. filed an 8-K on December 9, 2024, reporting an event that occurred on December 7, 2024. The filing pertains to Regulation FD Disclosure, Other Events, and Financial Statements and Exhibits. The company is incorporated in Delaware and headquartered in Cambridge, Massachusetts.
Why It Matters
This filing indicates important corporate events and disclosures for Beam Therapeutics, which could impact investors and stakeholders.
Risk Assessment
Risk Level: low — The filing is a standard 8-K report and does not contain specific negative or positive financial news.
Key Players & Entities
- Beam Therapeutics Inc. (company) — Registrant
- December 7, 2024 (date) — Earliest event reported
- December 9, 2024 (date) — Filing date
- Cambridge, Massachusetts (location) — Principal Executive Offices
FAQ
What is the primary purpose of this 8-K filing for Beam Therapeutics Inc.?
This 8-K filing serves as a Current Report for Beam Therapeutics Inc., covering Regulation FD Disclosure, Other Events, and Financial Statements and Exhibits.
On what date was the earliest event reported in this filing?
The earliest event reported in this filing occurred on December 7, 2024.
When was this 8-K form filed with the SEC?
This 8-K form was filed as of date December 9, 2024.
Where are Beam Therapeutics Inc.'s principal executive offices located?
Beam Therapeutics Inc.'s principal executive offices are located at 238 Main Street, Cambridge, Massachusetts, 02142.
What is the Commission File Number for Beam Therapeutics Inc.?
The Commission File Number for Beam Therapeutics Inc. is 001-39208.
Filing Stats: 1,707 words · 7 min read · ~6 pages · Grade level 13.7 · Accepted 2024-12-09 07:01:29
Key Financial Figures
- $0.01 — ich registered Common Stock, par value $0.01 per share BEAM Nasdaq Global Select
Filing Documents
- d903914d8k.htm (8-K) — 41KB
- d903914dex991.htm (EX-99.1) — 19KB
- d903914dex992.htm (EX-99.2) — 19KB
- g903914g1209043823599.jpg (GRAPHIC) — 3KB
- g903914g1209043854748.jpg (GRAPHIC) — 3KB
- g903914g1209043915979.jpg (GRAPHIC) — 3KB
- 0001193125-24-272860.txt ( ) — 226KB
- beam-20241207.xsd (EX-101.SCH) — 3KB
- beam-20241207_lab.xml (EX-101.LAB) — 17KB
- beam-20241207_pre.xml (EX-101.PRE) — 11KB
- d903914d8k_htm.xml (XML) — 3KB
Financial Statements and Exhibits
Financial Statements and Exhibits. (d) Exhibits Exhibit No Description 99.1 Press Release Issued by Beam Therapeutics Inc. on December 7, 2024 99.2 Press Release Issued by Beam Therapeutics Inc. on December 8, 2024 104 Cover Page Interactive Data File (embedded within the Inline XBRL document)
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Date: December 9, 2024 Beam Therapeutics Inc. By: /s/ John Evans Name: John Evans Title: Chief Executive Officer